FDA approves Procysbi for nephropathic cystinosis

FDA approves procysbi for nephropathic cystinosis
Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

(HealthDay)—Procysbi (cysteamine bitartrate) delayed-release capsules have been approved by the U.S. Food and Drug Administration to treat nephropathic cystinosis in children (6 years and up) and adults. Since it is intended to treat a rare disease or condition, Procysbi has been granted orphan product designation.

Affecting approximately 500 patients in the United States and an estimated 3,000 worldwide, cystinosis can lead to slow body growth and small stature, weak bones, and developing and worsening . Procysbi has been approved to treat the most severe form of cystinosis—nephropathic cystinosis.

A major study involving 43 patients found Procysbi to be as effective at controlling cystine levels as Cystagon, an immediate-release tablet approved by the FDA in 1994. Recorded common side effects included gastrointestinal discomfit, bad breath, constipation, headache, drowsiness, and dizziness. More severe but less common side effects included ulcers or bleeding of the stomach or intestine, altered mental state, seizures, severe skin rashes, and allergic reactions.

"Procysbi is the only delayed-release product approved by FDA to treat nephropathic cystinosis, offering patients with this an important new treatment option," Andrew E. Mulberg, M.D., deputy director of the Division of Gastroenterology and Inborn Errors Products in the FDA's Center for and Research, said in a statement.

Procysbi is manufactured by Raptor Pharmaceuticals, based in Novato, Calif.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA OKs drug to treat bleeding disorder

Apr 30, 2007

The U.S. Food and Drug Administration has approved Humate-P for the treatment of a specific bleeding disorder called von Willebrand disease.

Iclusig approved for rare leukemias

Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Recommended for you

Health care M&A leads global deal surge

10 hours ago

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.